Northern Trust’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Northern Trust’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,853	Closed	-$22.4K	–	4641
2023 Q1	$22.4K	Hold	1,853	–	–	﹤0.01%	4429
2022 Q4	$8.43K	Hold	1,853	–	–	﹤0.01%	4589
2022 Q3	$12K	Hold	1,853	–	–	﹤0.01%	4629
2022 Q2	$20K	Sell	1,853 -7,166	-79%	-$96.4K	﹤0.01%	4630
2022 Q1	$172K	Sell	9,019 -442	-5%	-$9.85K	﹤0.01%	4183
2021 Q4	$339K	Buy	9,461 +140	+2%	+$7.97K	﹤0.01%	3964
2021 Q3	$685K	Buy	9,321 +3,605	+63%	+$277K	﹤0.01%	3661
2021 Q2	$797K	Sell	5,716 -776	-12%	-$136K	﹤0.01%	3586
2021 Q1	$1.89M	Buy	+6,492	New	+$2.58M	﹤0.01%	3276

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's SGTX Position: Q2 2023 in Review

Northern Trust sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 1,853 shares — an estimated $22.4K sold.

Northern Trust first reported a position in SGTX in Q1 2021 and held it in 9 quarters. The position peaked at $1.89M in Q1 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Northern Trust reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 1,853 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $22.4K.
Northern Trust first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Northern Trust's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.89M in Q1 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.